AJ Palmer, L Annemans, S Roze, M Lamotte, P … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This study was a Markov model–simulated
progression from microalbuminuria to overt nephropathy, doubling of serum
creatinine, end-stage renal disease, and death in hypertensive patients ... Cited by 38 - Related articles - BL Direct - All 8 versions
AJ Palmer, L Annemans, S Roze, M Lamotte, … - Journal of human hypertension, 2004 - nature.com There are substantial healthcare costs associated with the provision of renal
replacement therapy. Patients with diabetes mellitus are the largest and fastest
growing group developing end-stage renal disease (ESRD) in the United ... Cited by 27 - Related articles - BL Direct - All 5 versions
- ►oxfordjournals.org AJ Palmer, L Annemans, S Roze, M Lamotte, … - Nephrology Dialysis Transplantation, 2003 - ERA-EDTA Methods. A Markov model simulated progression from nephropathy to DSC, ESRD and
death in patients with hypertension, type 2 diabetes and overt nephropathy.
Treatment-specific probabilities were derived from IDNT. Country-specific ... Cited by 39 - Related articles - BL Direct - All 4 versions
AJ Palmer, L Annemans, S Roze, P Lapuerta, … - Kidney International, 2005 - nature.com A peer-reviewed, published Markov model that simulated progression from
microalbuminuria to nephropathy, doubling of serum creatinine, ESRD, and
all-cause mortality in patients with hypertension, type 2 diabetes, and ... Cited by 14 - Related articles - All 3 versions
AJ Palmer, WJ Valentine, R Chen, N Mehin, … - Nephrology Dialysis Transplantation, 2008 - ERA-EDTA Background. Nephropathy is an indicator of end-organ damage and is a strong
predictor of an increased risk of cardiovascular disease and death in patients
with diabetes. Screening can lead to early identification and treatment, ... Cited by 7 - Related articles - BL Direct - All 6 versions
RA Rodby, CF Chiou, J Borenstein, A … - Clinical therapeutics, 2003 - Elsevier Methods: Three treatments for hypertensioe patients with type 2 diabetes
mellitus and nephropathy were assessed: (1) irbesartan, (2) amlodipine, and (3)
placebo. A Markov model was developed based on primary data from the ... Cited by 35 - Related articles - All 5 versions
AJ Palmer, WJ Valentine, JA Ray - International journal of clinical practice, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 2 - Related articles - BL Direct - All 4 versions
AJ Palmer, WJ Valentine, JA Ray, S Roze, N … - The European Journal of Health Economics, 2007 - Springer Abstract To perform a health economic analysis on treatment with irbesartan in
patients with type 2 dia- betes and hypertension. A Markov model was adapted to
the Hungarian setting to simulate renal deterioration from the development ... Cited by 3 - Related articles - BL Direct - All 4 versions
AJ Palmer, WJ Valentine, DMD Tucker, JA Ray … - Current Medical Research and Opinion®, 2006 - informahealthcare.com Andrew J. palmer a, William J. Valentine a, daniel M. d. tucker a, Joshua A. ray
a, stéphane roze a, lieven Annemans b,c, pablo lapuerta d, roland Chen d,
sylvie Gabriel e, paulo Carita e, roger A. rodby f, dick de Zeeuw g, ... Cited by 8 - Related articles - BL Direct - All 6 versions
- ►oxfordjournals.org AJ Palmer, D Tucker, WJ Valentine, S Roze, S … - Nephrology Dialysis Transplantation, 2005 - ERA-EDTA Methods. Articles were identified based on a search of the PubMed databases
using the keywords 'irbesartan', 'ESRD', 'cost-effectiveness', 'nephropathy' and
'costs', and by personal communication with the authors. Only studies ... Cited by 16 - Related articles - All 5 versions
